Ranjit S. Bindra, MD, PhD

Associate Professor of Therapeutic Radiology

Research Departments & Organizations

Therapeutic Radiology: Radiobiology


Yale Cancer Center: Radiobiology & Radiotherapy

Office of Cooperative Research

Research Interests

Central Nervous System Neoplasms; DNA Repair; Genomics; Glioma; High-Throughput Screening Assays; Medical Oncology; Pediatrics; Radiation Oncology; Radiology; Therapeutics

Extensive Research Description

My research is focused on the development of novel cell-based assays for high-throughput screening using genetic and small molecule approaches, both for the creation of novel therapeutics and for new pathway discovery. In addition, I am interested in the development of synthetic lethal targeting strategies for the treatment of tumors with unique genetic aberrations. Clinically, I am focused on the treatment of adult and pediatric CNS tumors. I am interested in leveraging my translational research and clinical experience as a physician-scientist to conduct future investigator-initiated Phase I trials at Yale, based on the results of the drug and genomics screening efforts in my laboratory. I recently completed my residency in radiation oncology at Memorial Sloan-Kettering Cancer Center (MSKCC), and I joined the faculty in the Department of Therapeutic Radiology at Yale in the summer of 2012. I was given the opportunity to pursue a brief period of protected research during residency at MSKCC, which I completed in July 2012. This research time was supported by the Leonard B. Holman Pathway fellowship program. During this time, I developed a high-throughput assay for DNA repair inhibitors, which was published in Nucleic Acids Research. We subsequently utilized this assay in a high-throughput screen for novel DNA repair inhibitors, which identified several novel glioma radiosensitizers. A manuscript from my independent laboratory describing the results was recently published in Molecular Cancer Therapeutics. Our laboratory also recently developed a novel, next-generation sequencing-based assay to measure DNA repair at endogenous loci, which was recently published in DNA Repair. Finally, I recently translated a drug from this screen directly into a Phase I clinical trial for recurrent adult glioma patients. I am the PI of this trial, NCT02202993, which opened for enrollment in August 2014. This work, coupled with my research and publications during my PhD, have equipped me with the necessary skills and experience to begin a career as an independent investigator pursuing highly translational projects.

Clinical Trials

Conditions Study Title
Prostate Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)
Breast - Female Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma
Esophagus, Larynx, Lip, Oral Cavity and Pharynx Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Brain and Nervous System Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Lung Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Brain and Nervous System, Pediatrics A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Edit this profile

Contact Info

Ranjit S. Bindra, MD, PhD
Office Location
Yale Therapeutic RadiologyHunter Building
15 York Street, Ste HRT 313C

New Haven, CT 06510
Mailing Address
Therapeutic RadiologyP. O. Box 208040
New Haven, CT 06520-8040

Curriculum Vitae